Paper21477288
Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer.
Fujisawa T and 2 others. J Transl Med, 2011. Cited by 27 papers, by iCite.
Cite this record
ConductScience Library. Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer. Papers, record 21477288. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21477288
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer.
- PubMed
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Histones | Major topic |
| Immunotoxins | Major topic |
| Pancreatic Neoplasms | Major topic |
| Protein Processing, Post-Translational | Major topic |
| Receptors, Interleukin-13 | Major topic |
| Acetylation | |
| Animals | |
| Base Sequence | |
| Cell Line, Tumor | |
| DNA Methylation | |
| DNA Mutational Analysis | |
| DNA, Complementary | |
| Disease Models, Animal | |
| Gene Expression Regulation, Neoplastic | |
| Histone Deacetylase Inhibitors | |
| Humans | |
| Interleukin-13 | |
| Matrix Metalloproteinases | |
| Mice | |
| Promoter Regions, Genetic | |
| Transcription Factor AP-1 | |
| Up-Regulation | |
| Xenograft Model Antitumor Assays |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16264908 | Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. | Nat Clin Pract Oncol | 2005 | https://conductscience.org/library/papers/16264908 | PubMed |
| 2 | 8639793 | Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). | Blood | 1996 | https://conductscience.org/library/papers/8639793 | PubMed |
| 3 | 15164071 | Epigenetics in human disease and prospects for epigenetic therapy. | Nature | 2004 | https://conductscience.org/library/papers/15164071 | PubMed |
| 4 | 11882541 | Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. | EMBO Rep | 2002 | https://conductscience.org/library/papers/11882541 | PubMed |
| 5 | 19833297 | Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. | Lancet Neurol | 2009 | https://conductscience.org/library/papers/19833297 | PubMed |
| 6 | 9815666 | Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. | Clin Cancer Res | 1997 | https://conductscience.org/library/papers/9815666 | PubMed |
| 7 | 7622490 | A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. | J Biol Chem | 1995 | https://conductscience.org/library/papers/7622490 | PubMed |
| 8 | 19010904 | Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy. | Cancer Res | 2008 | https://conductscience.org/library/papers/19010904 | PubMed |
| 9 | 9815919 | Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. | Clin Cancer Res | 1995 | https://conductscience.org/library/papers/9815919 | PubMed |
| 10 | 12816724 | Molecular cloning and identification of the human interleukin 13 alpha 2 receptor (IL-13Ra2) promoter. | Neuro Oncol | 2003 | https://conductscience.org/library/papers/12816724 | PubMed |
| 11 | 16618770 | Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain. | Cancer Res | 2006 | https://conductscience.org/library/papers/16618770 | PubMed |
| 12 | 15604287 | Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. | Cancer Res | 2004 | https://conductscience.org/library/papers/15604287 | PubMed |
| 13 | 12445278 | Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. | Immunol Rev | 2002 | https://conductscience.org/library/papers/12445278 | PubMed |
| 14 | 15642470 | Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli. | Protein Expr Purif | 2005 | https://conductscience.org/library/papers/15642470 | PubMed |
| 15 | 19887609 | A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. | Cancer Res | 2009 | https://conductscience.org/library/papers/19887609 | PubMed |
| 16 | 11696577 | Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. | J Clin Invest | 2001 | https://conductscience.org/library/papers/11696577 | PubMed |
| 17 | 12060640 | Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. | Clin Cancer Res | 2002 | https://conductscience.org/library/papers/12060640 | PubMed |
| 18 | 19861533 | Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. | Cancer Res | 2009 | https://conductscience.org/library/papers/19861533 | PubMed |
| 19 | 18665158 | Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. | Mol Ther | 2008 | https://conductscience.org/library/papers/18665158 | PubMed |
| 20 | 20068108 | Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. | Clin Cancer Res | 2010 | https://conductscience.org/library/papers/20068108 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40542937 | Advances in the Optimization of CAR-T-Cell-Based Therapeutic Approaches to Enhance Antitumor Efficacy in Glioblastoma Treatment. | Oncol Ther | 2025 | https://conductscience.org/library/papers/40542937 | PubMed |
| 38685487 | Identification and characterisation of novel CAR-T cells to target IL13Rα2 positive human glioma in vitro and in vivo. | Clin Transl Med | 2024 | https://conductscience.org/library/papers/38685487 | PubMed |
| 38573683 | Applications and Opportunities for Immune Cell CAR Engineering in Comparative Oncology. | Clin Cancer Res | 2024 | https://conductscience.org/library/papers/38573683 | PubMed |
| 37345109 | Targeting and Sensitization of Breast Cancer Cells to Killing with a Novel Interleukin-13 Receptor α2-Specific Hybrid Cytolytic Peptide. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37345109 | PubMed |
| 36830725 | Targeting of the Interleukin-13 Receptor (IL-13R)α2 Expressing Prostate Cancer by a Novel Hybrid Lytic Peptide. | Biomolecules | 2023 | https://conductscience.org/library/papers/36830725 | PubMed |
| 35464460 | Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy. | Front Immunol | 2022 | https://conductscience.org/library/papers/35464460 | PubMed |
| 34201539 | IL-13Rα2 Is a Biomarker of Diagnosis and Therapeutic Response in Human Pancreatic Cancer. | Diagnostics (Basel) | 2021 | https://conductscience.org/library/papers/34201539 | PubMed |
| 34198989 | Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34198989 | PubMed |
| 33804263 | Involvement of IL-4, IL-13 and Their Receptors in Pancreatic Cancer. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33804263 | PubMed |
| 32443847 | A Novel Role of Interleukin 13 Receptor alpha2 in Perineural Invasion and its Association with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32443847 | PubMed |
| 31607839 | Five Novel Genes Related to the Pathogenesis and Progression of Pancreatic Neuroendocrine Tumors by Bioinformatics Analysis With RT-qPCR Verification. | Front Neurosci | 2019 | https://conductscience.org/library/papers/31607839 | PubMed |
| 27623944 | IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway. | Tumour Biol | 2016 | https://conductscience.org/library/papers/27623944 | PubMed |
| 25799412 | SCF, regulated by HIF-1α, promotes pancreatic ductal adenocarcinoma cell progression. | PLoS One | 2015 | https://conductscience.org/library/papers/25799412 | PubMed |
| 25346520 | Engineering toxin-resistant therapeutic stem cells to treat brain tumors. | Stem Cells | 2015 | https://conductscience.org/library/papers/25346520 | PubMed |
| 23533247 | TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. | Endocr Relat Cancer | 2013 | https://conductscience.org/library/papers/23533247 | PubMed |
| 22981627 | The future of human DNA vaccines. | J Biotechnol | 2012 | https://conductscience.org/library/papers/22981627 | PubMed |
| 22770803 | Targeting the MAGE A3 antigen in pancreatic cancer. | Surgery | 2012 | https://conductscience.org/library/papers/22770803 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| HDAC9 | 9734 | PubTator's text mining | https://conductscience.org/library/genes/9734 | NCBI Gene |
| IL13 | 3596 | PubTator's text mining | https://conductscience.org/library/genes/3596 | NCBI Gene |
| IL13RA2 | 3598 | PubTator's text mining | https://conductscience.org/library/genes/3598 | NCBI Gene |
| JUN | 3725 | PubTator's text mining | https://conductscience.org/library/genes/3725 | NCBI Gene |
| JUNB | 3726 | PubTator's text mining | https://conductscience.org/library/genes/3726 | NCBI Gene |
| POTEF | 728378 | PubTator's text mining | https://conductscience.org/library/genes/728378 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21477288
GET https://conductscience.org/api/papers/v1/21477288/references?page=2